Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,421 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05391750 | Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma | active not recruiting | Phase 1 | 7 | Emory UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06212323 | Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial(SPOTLIGHT) | recruiting | — | 100 | University of UtahOTHER | 1 | Feb 17, 2026 |
| NCT07403630 | INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)(IT-TCP POS) | recruiting | N/A | 300 | Azienda Ospedaliero-Universitaria di ParmaOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07413809 | Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen | recruiting | Phase 3 | 92 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07333261 | Study of BMS-986453 in Newly Diagnosed Multiple Myeloma | recruiting | Phase 1 | 25 | Susan BalOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07410403 | AI-Based Fine Morphological Subtyping of Myeloma Single Cells for Predicting FISH Abnormalities(AI) | enrolling by invitation | — | 10 | Fuling ZhouOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT04645199 | National Longitudinal Cohort of Hematological Diseases(NICHE) | recruiting | — | 2,300 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06099912 | Individualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMM(DynaFiT) | recruiting | — | 131 | FengYan JinOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07407010 | BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM(CM336-001) | not yet recruiting | Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Feb 12, 2026 | clinicaltrials |
| NCT04977024 | SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer | active not recruiting | Phase 2 | 63 | GeoVax, Inc.INDUSTRY | 1 | Feb 11, 2026 | clinicaltrials |
| NCT05396885 | Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)(iMMagine-1) | active not recruiting | Phase 2 | 136 | Kite, A Gilead CompanyINDUSTRY | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07403071 | Validating Fish Oil's Role in Alleviating Bortezomib-Induced Neuropathy: A Multi-Method Study Integrating Big Data, Experimental, and Clinical Research | not yet recruiting | — | 200 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Feb 11, 2026 | clinicaltrials |
| NCT03710603 | Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma(Perseus) | active not recruiting | Phase 3 | 709 | Stichting European Myeloma NetworkNETWORK | 13 | Feb 10, 2026 | clinicaltrials |
| NCT04221178 | Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission | active not recruiting | — | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT04751877 | Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). | active not recruiting | Phase 3 | 270 | Poitiers University HospitalOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT06015542 | Self-administration of Subcutaneous Elranatamab in the Patients' Homes.(ERICA) | recruiting | Phase 2 | 20 | Thomas LundOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT07234721 | SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma(SL4903) | not yet recruiting | Early Phase 1 | 9 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Feb 10, 2026 | clinicaltrials |
| NCT07399444 | A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma(LB2505-0001)(LB2505-0001) | not yet recruiting | Early Phase 1 | 38 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT07400744 | A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects | not yet recruiting | Phase 1 | 102 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Feb 10, 2026 | clinicaltrials |
| NCT04850846 | Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma | active not recruiting | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT03933735 | A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 220 | AbbVieINDUSTRY | 2 | Feb 6, 2026 | clinicaltrials |
| NCT06280924 | Prehab Prior to Stem Cell Transplantation in Multiple Myeloma(MOTIVATE) | recruiting | N/A | 30 | University of AlbertaOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT00572169 | UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy | active not recruiting | Phase 3 | 177 | University of ArkansasOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05093335 | In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET | recruiting | Early Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06574568 | A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 70 | Excyte Biopharma LtdINDUSTRY | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07390071 | Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy | recruiting | N/A | 40 | University of UtahOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07388147 | Exercise Therapy for Multiple Myeloma Patients(SAPPHIRE-MM) | not yet recruiting | N/A | 71 | University Hospital HeidelbergOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT03617731 | Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7) | active not recruiting | Phase 3 | 662 | University of Heidelberg Medical CenterOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT04414475 | A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. | recruiting | Phase 2 | 127 | Karyopharm Therapeutics IncINDUSTRY | 2 | Feb 2, 2026 | clinicaltrials |
| NCT07297329 | A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | recruiting | Phase 3 | 292 | Sinocelltech Ltd.INDUSTRY | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07376720 | A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment | not yet recruiting | N/A | 28 | Donghua ZhangOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07376733 | Effects of Controlled Breathing on Cardiorespiratory Variables in Multiple Myeloma | not yet recruiting | N/A | 26 | Universidad Complutense de MadridOTHER | 0 | Jan 29, 2026 | clinicaltrials |
| NCT01199562 | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | active not recruiting | — | 153 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT04240054 | Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency(VICD) | recruiting | Phase 2 | 41 | Medical College of WisconsinOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07369895 | Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 18 | O&D BioTech Group CO., LimitedINDUSTRY | 1 | Jan 27, 2026 | clinicaltrials |
| NCT00582621 | Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders | recruiting | — | 500 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT01208662 | Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65(DFCI 10-106) | active not recruiting | Phase 3 | 729 | Paul Richardson, MDOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT02718833 | A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma | active not recruiting | Phase 2 | 52 | Massachusetts General HospitalOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05706766 | Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation | recruiting | N/A | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT06357754 | Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy | recruiting | — | 50 | Bristol-Myers SquibbINDUSTRY | 4 | Jan 22, 2026 | clinicaltrials |
| NCT07044427 | Fall Risk Assessment and an Exercise Intervention for Prevention of Falls in Multiple Myeloma Patients(Myfall) | recruiting | N/A | 60 | University Hospital HeidelbergOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07305662 | Exploring the Effects of Korean-Style Mediterranean Diet (KORMED) and Physical Activity Measurement in Patients With MGUS/SMM: A Pilot Study(KORMED-PA Stud) | not yet recruiting | N/A | 20 | Seoul National University Bundang HospitalOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05366881 | cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease(CAMPERR) | recruiting | — | 7,000 | Adela, IncINDUSTRY | 1 | Jan 20, 2026 | clinicaltrials |
| NCT07185490 | IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma(IASO104) | not yet recruiting | Early Phase 1 | 40 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jan 20, 2026 | clinicaltrials |
| NCT07312942 | Effects of Controlled Breathing Added to Therapeutic Exercise in Multiple Myeloma | not yet recruiting | N/A | 32 | Universidad Complutense de MadridOTHER | 0 | Jan 20, 2026 | clinicaltrials |
| NCT07353554 | Application Study of 68Ga-NOTA-BCMA Nanoantibody Imaging in Multiple Myeloma | not yet recruiting | N/A | 30 | Peking Union Medical College HospitalOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT04586426 | A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma(RedirecTT-1) | active not recruiting | Phase 1 / Phase 2 | 228 | Janssen Research & Development, LLCINDUSTRY | 7 | Jan 16, 2026 | clinicaltrials |
| NCT07348393 | A Phase 2, Single Arm Multicenter, Study Testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)(Mezi-KD) | not yet recruiting | Phase 2 | 70 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT01269593 | PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study | active not recruiting | Early Phase 1 | 63 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 15, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Feb 17, 2026source: clinicaltrials